Inoperable non–small-cell lung cancer has become the domain of combined-modality treatment based on several recent, large, phase III studies. Results of Radiation Therapy Oncology Group (RTOG) phase II studies have
Roger W. Byhardt, MD
Advertisement
Articles by Roger W. Byhardt, MD
Advertisement
Latest Updated Articles
- Toxicities in RTOG Combined-Modality Trials for Inoperable Non–Small-Cell Lung Cancer
Published: October 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Pembrolizumab Formulation in Solid Tumors
2
Cevostamab Post-CAR T-Cell Therapy is Safe in Heavily Pretreated Multiple Myeloma
3
ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors
4
BPd Maintenance Safe, Yields Responses in High-Risk Multiple Myeloma
5
